Acrivon Therapeutics, Inc.
ACRV
$1.52
-$0.06-3.80%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.12M | 25.08M | 25.32M | 25.26M | 25.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 84.11M | 88.95M | 94.41M | 93.19M | 89.20M |
| Operating Income | -84.11M | -88.95M | -94.41M | -93.19M | -89.20M |
| Income Before Tax | -77.91M | -81.75M | -85.96M | -83.75M | -80.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -77.91 | -81.75 | -85.96 | -83.75 | -80.56 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -77.91M | -81.75M | -85.96M | -83.75M | -80.56M |
| EBIT | -84.11M | -88.95M | -94.41M | -93.19M | -89.20M |
| EBITDA | -82.76M | -87.65M | -93.21M | -92.10M | -88.19M |
| EPS Basic | -2.02 | -2.13 | -2.25 | -2.22 | -2.44 |
| Normalized Basic EPS | -1.27 | -1.39 | -1.47 | -1.45 | -1.58 |
| EPS Diluted | -2.02 | -2.13 | -2.25 | -2.22 | -2.44 |
| Normalized Diluted EPS | -1.27 | -1.39 | -1.47 | -1.45 | -1.58 |
| Average Basic Shares Outstanding | 154.03M | 153.61M | 153.16M | 150.83M | 135.07M |
| Average Diluted Shares Outstanding | 154.03M | 153.61M | 153.16M | 150.83M | 135.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |